

Serial No. 10/698,664  
Reply to Office Action of March 1, 2004

**Amendments to the Claims:**

This listing of claims will replace all prior versions, and listings, of claims in the application.

**Listing of Claims:**

1. (Original) Crystalline form II of cabergoline having the IR spectrum of Figure 3.
2. (Original) Crystalline form II of cabergoline according to claim 1 which is anhydrous, non-solvated and has a percentage purity greater than 85%.
3. (Original) Crystalline form II of cabergoline according to claim 1 which is anhydrous, non-solvated and has a percentage purity greater than 98%.
4. (Original) A pharmaceutical composition which comprises an effective amount of crystalline Form II as defined in claim 1 in combination with one or more pharmaceutically acceptable carriers, excipients, diluents or adjuvants.
5. (Original) A process for producing cabergoline Form II as defined in claim 1 which process comprises crystallisation of the desired form II from a solution of raw cabergoline in an organic solvent at a low temperature.
6. (Original) A process according to claim 5 in which the organic solvent is a ketone, an acetal, a linear ether, an ester or a mixture thereof.
7. (Original) A process according to claim 5 in which the solvent is diethyl ether or methyl tert-butyl ether.
8. (Original) A process for producing cabergoline Form II as defined in claim 1, which process comprises subjecting a mixture of cabergoline forms I and II in a solvent at a temperature below about 30°C to a slurry procedure.
9. (Original) A process according to claim 8 in which the solvent is diethyl ether or n-hexane.

Serial No. 10/698,664  
Reply to Office Action of March 1, 2004

10. (Original) Crystalline form II of cabergoline having the DSC curve of Figure 2.
11. (Original) Crystalline form II of cabergoline according to claim 10 which is anhydrous, non-solvated and has a percentage purity greater than 85%.
12. (Currently amended) Crystalline form II of cabergoline according to claim [[1]] 10 which is anhydrous, non-solvated and has a percentage purity greater than 98%.
13. (Original) A pharmaceutical composition which comprises an effective amount of crystalline Form II as defined in Claim 10 in combination with one or more pharmaceutically acceptable carriers, excipients, diluents or adjuvants.
14. (Original) A process for producing cabergoline Form II as defined in Claim 10, which process comprises crystallisation of the desired form II from a solution of raw cabergoline in an organic solvent at a low temperature.
15. (Original) A process according to claim 14 in which the organic solvent is a ketone, an acetal, a linear ether, an ester or a mixture thereof.
16. (Original) A process according to Claim 14 in which the solvent is diethyl ether or methyl tert-butyl ether.
17. (Original) A process for producing cabergoline Form II as defined in Claim 10, which process comprises subjecting a mixture of cabergoline forms I and II in a solvent at a temperature below about 30°C to a slurry procedure.
18. (Original) A process according to claim 17 in which the solvent is diethyl ether or n-hexane.
19. (New) Crystalline form II of cabergoline having an XRD powder pattern exhibiting peaks at approximately 8.5, 9.4, 11.6, 16.5 and 21.5 deg 2-theta.